Pertuzumab for the Neoadjuvant Treatment of Early-Stage HER2-Positive Breast Cancer: An Evidence Review Group Perspective of a NICE Single Technology Appraisal

As part of its single technology appraisal process, the National Institute for Health and Care Excellence invited the manufacturer of pertuzumab (Perjeta ® ; Roche Products Limited) to submit evidence of its clinical and cost- effectiveness for the neoadjuvant treatment of women with high-risk, earl...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	PharmacoEconomics 2018, Vol.36 (1), p.29-38
Hauptverfasser:	Squires, Hazel, Pandor, Abdullah, Thokala, Praveen, Stevens, John W., Kaltenthaler, Eva, Clowes, Mark, Coleman, Robert, Wyld, Lynda
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal, Humanized - administration & dosage Antineoplastic Combined Chemotherapy Protocols - administration & dosage Antineoplastic Combined Chemotherapy Protocols - economics Breast cancer Breast Neoplasms - drug therapy Breast Neoplasms - economics Cancer therapies Chemotherapy Cost analysis Cost-Benefit Analysis Docetaxel - administration & dosage Dosage and administration Economic models Female Health Administration Health Economics Health services Humans Immunotherapy Medical prognosis Medicine Medicine & Public Health Metastasis Models, Economic Monoclonal antibodies Neoadjuvant therapy Neoadjuvant Therapy - methods Neoplasm Staging Patients Pertuzumab Pharmacoeconomics and Health Outcomes Public Health Quality of Life Research Quality-Adjusted Life Years Randomized Controlled Trials as Topic Receptor, ErbB-2 - metabolism Review Article Surgery Systematic review Targeted cancer therapy Technology Assessment, Biomedical - methods Trastuzumab - administration & dosage Womens health
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!